RxDoctor Payments Data

da Ouyang, MD

Cardiovascular Disease · Santa Clara, CANPI 1235549460

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,600 of the $1,784 with a category attached, or 89.7%. Pfizer accounts for 89.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $1,600 and has fallen 92.4% since, to $121 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.

$1,784in general payments, 2019–2025

Across 4 payments — averaging $446.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • E.r. Squibb & Sons, L.L.C.$163
  • Fujifilm Sonosite, Inc.$21
$772,631in research payments, 2019–2025

Across 4 payments — averaging $193,158 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$773K

What the payments were for

  • Speaking & faculty fees$1,60090%
  • Food & beverage$18410%

General payments by program year

20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,784 in reported general payments places this provider in the 45th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$38,375
Medicare patients
326
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Santa Clara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →